In March, Moderna announced it will build a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots. The pharmaceutical company will invest $500 million in the Kenyan facility, and supply as many as 500 million doses of mRNA vaccines to the continent each year.

Join Hazel Sive, dean of Northeastern’s College of Science and chair of the Africa Global Initiative, to hear from Patrick Bergstedt about how Moderna’s presence in Kenya will also help develop treatments for other diseases and position the continent to respond to future health crises.

Following the lecture, guests are invited to gather for a reception in the ISEC Atrium.